Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > Ifenprodil phase 3
View:
Post by B52paul on Feb 24, 2021 3:50pm

Ifenprodil phase 3


Comment by B52paul on Feb 24, 2021 3:54pm
ALGERNON PHARMACEUTICALS’ NP-120 (IFENPRODIL) OUTPERFORMS MERCK’S PHASE 3 DRUG MK-7264 (GEFAPIXANT) IN AN ACUTE COUGH STUDY BY 110% https://www.cbj.ca/algernon-pharmaceuticals-np-120-ifenprodil-outperforms-mercks-phase-3-drug-mk-7264-gefapixant-in-an-acute-cough-study-by-110/
Comment by GoodLife60 on Feb 24, 2021 4:34pm
this is from 2019!
Comment by hk1966 on Feb 24, 2021 6:35pm
Old news..nice pump job. From Dec.2019
Comment by Bradwait on Feb 24, 2021 8:06pm
It does show its a potent drug and now being used for Covid, so that is relevant. It kicked the butt of a drug by a multi billion dollar cap big pharma.  https://stockhouse.com/companies/bullboard?symbol=c.agn&postid=32643181
Algernon Pharmaceuticals Inc.